Lakefront Biotherapeutics NV (LKFT) earnings
In the quarter ended June 2021, Lakefront Biotherapeutics NV had revenue of 140M EUR, up 419.0% on a year earlier.
Quarterly results
The last 5 quarters from Lakefront Biotherapeutics NV's 10-Q and 10-K filings with the SEC, in EUR. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2021 | 140M EUR | +419.0% | — | — | -33.4% | 2021-08-05 |
| Jun 30, 2020 | 100M EUR | — | — | — | -88.5% | 2020-08-06 |
| Jun 30, 2019 | 59M EUR | — | — | — | -75.5% | 2019-07-25 |
| Jun 30, 2018 | 50M EUR | — | — | — | -67.9% | 2018-08-02 |
| Jun 30, 2017 | 27M EUR | — | — | — | -80.5% | 2018-08-02 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LKFT.
Open LKFT in InvestinglyQuestions
How did Lakefront Biotherapeutics NV do last quarter?
In the quarter ended June 2021, Lakefront Biotherapeutics NV had revenue of 140M EUR, up 419.0% on a year earlier.
From Lakefront Biotherapeutics NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.